QGEN — QIAGEN N.V.

—
NYSE · Health Care · Biotechnology · CIK 1015820 · Netherlands
Last close
$49.75
Market Cap
$10.27B
52W High
$57.30
52W Low
$32.24
ADV30
5,047,125
Next earnings
2027-02-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 547,869,000 354,000,000 151,643,000 105,659,000 5,942,470,000 805,132,000 2,467,508,000
Jun 2026 535,040,000 340,386,000 140,850,000 103,401,000 5,889,202,000 768,500,000 2,531,462,000
Mar 2026 492,320,000 309,603,000 116,626,000 68,043,000 5,782,065,000 646,289,000 2,450,359,000
Dec 2025 540,420,000 325,269,000 121,880,000 107,829,000 6,281,232,000 839,005,000 2,503,078,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$654,470,000
Investing CF
$-242,149,000
Financing CF
$-376,407,000
CapEx
$-213,873,000
Dividends Paid
$1,000
Buybacks
$0
EPS Diluted TTM
$1.98
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$2,814,982,000
Inventory
$311,355,000
Receivables
$389,850,000
ST Investments
$25,000,000
EBIT TTM
$501,259,000
Pretax Income TTM
$461,829,000
Interest Exp TTM
$39,430,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,100,363,008
EBITDA
$734,185,024
Free Cash Flow
$372,855,136
Enterprise Value
$9,636,236,288
Total Cash
$793,500,032
Total Debt
$1,653,698,944
Shares Out
206,495,000
Trailing EPS
$1.97
Book Value
$16.26
ROE
11.9%
ROA
5.9%
Div Yield
0.83%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,089,999,000 520,310,000 424,880,000 6,281,232,000 2,503,078,000 3,778,154,000 654,326,000
Dec 2024 1,978,214,000 199,899,000 83,591,000 5,689,622,000 2,122,283,000 3,567,339,000 673,551,000
Dec 2023 1,965,311,000 445,247,000 341,303,000 6,115,190,000 2,307,426,000 3,807,764,000 459,455,000
Dec 2022 2,141,518,000 576,228,000 423,211,000 6,287,735,000 2,821,124,000 3,466,611,000 715,264,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.61

Max Pain — expiry 2026-12-18

max pain strike: $45.00 · spot: $49.56 · call oi: 14,546 · put oi: 3,245
Expected Move to 2026-12-18: ±$0.88 (1.77%) — implied range $48.69 – $50.44 · ATM straddle on $50.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RGEN REPLIGEN CORP $10.30B $162.18 —
KYMR Kymera Therapeutics, Inc. $10.37B $121.52 —
HALO HALOZYME THERAPEUTICS, INC. $10.94B $95.97 —
PCVX Vaxcyte, Inc. $9.40B $59.40 —
TECH BIO-TECHNE Corp $11.41B $72.63 —

News headlines (Yahoo Finance, 1h cache)

Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen
2026-11-12 15:00 · Yahoo
RNA Interference (RNAi) - Global Strategic Business Report: Capture the US$8 Billion 2032 Market as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Qiagen, Benitec BioPharma, and Silence Therapeutics
2026-11-12 14:06 · Yahoo
Transfection Technologies - Global Strategic Business Report 2026: Capitalize on a $2.5 Billion Market by 2032 as Thermo Fisher, Lonza, Bio-Rad, Qiagen and MilliporeSigma Accelerate
2026-11-11 14:21 · Yahoo
Human Identification - Global Strategic Business Report 2026: Capitalize on 10.1% CAGR to $1.9 Billion by 2032 | Thermo Fisher, Illumina, Qiagen and Bio-Rad Vie for Shares
2026-11-11 14:15 · Yahoo
Epigenetics - Global Strategic Business Report: Capitalize on an 18.2% CAGR to Secure the $5.5 Billion 2030 Market as Illumina, Thermo Fisher Scientific, Qiagen, and Bio-Rad Disrupt Precision Medicine
2026-11-11 14:12 · Yahoo
Qiagen (QGEN) Shareholders Approve Jonathan M Pratt As CEO And Managing Director
2026-11-11 12:17 · Yahoo
Electrophoresis Reagents - Global Strategic Business Report: Capitalize on China's 7.4% CAGR as Bio-Rad, QIAGEN, Agilent, Merck Millipore and Thermo Fisher Battle for $1.3B by 2032
2026-11-10 15:09 · Yahoo
Nucleic Acid Isolation and Purification - Global Strategic Business Report: Capture the $3.9 Billion Revenue Surge by 2030 as Thermo Fisher, Qiagen, Danaher, Illumina, and Bio-Rad Battle for Share
2026-11-10 15:02 · Yahoo
Gene Panels - Global Strategic Business Report 2026: Capitalize on 17.9% CAGR as Market Triples to $12.6B by 2032 - Track Key Players Illumina, Roche, QIAGEN, Thermo Fisher, Agilent and More
2026-11-10 14:24 · Yahoo
Personalized Medicines - Global Strategic Business Report 2026: Capitalize on the $496.6B Market by 2032 | Competitive Intelligence on Roche, Novartis, Abbott Molecular and QIAGEN
2026-11-10 14:19 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.